Skip to Content

BE MOBILE 2: Bimekizumab in patients with active ankylosing spondylitis

In this MEDtalk, Professor in rheumatology Désirée Van Der Heijde, presents the 24-week results from the BE-MOBILE 2 study, suggesting a significant treatment efficacy in patients with active ankylosing spondylitis receiving bimekizumab (160 mg/4 week) versus placebo.

Désirée Van Der Heijde

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top